Today we announced $35M in additional funding from Shenzhen Salubris – to advance our ongoing Phase 2 study of the first clinical-stage, selective ErbB4 agonist JK07 in Heart Failure (reduced and preserved ejection fraction), ongoing monotherapy and combination cohorts for the first IL15-CTLA4 antibody fusion JK08 in the treatment of solid tumors, and initiation of clinical development for our first-in-class biparatopic ADC JK06. We already have the first patient enrolled in RENEU-HF, our 282-subject Phase 2 study of JK07 in Heart Failure, the first patient dosed with JK08 and pembrolizumab combination treatment, and the clinical trial application for JK06 has been filed. We look forward to sharing meaningful updates on all of these clinical-stage programs later this year.
https://lnkd.in/ezvK8siY